Article | March 22, 2022

Advancing Novel Therapeutics With End-To-End Lipid Nanoparticle Development And Manufacturing

Source: Evonik Corporation

By Natalia Zisman, Senior Manager, Technical Marketing, Evonik


Lipid nanoparticles (LNPs) are crucial to the successful delivery of mRNA vaccines and other RNA and nucleic acid therapeutics. Developers of these novel products need the support of a collaborative partner such as Evonik with extensive experience working with all type of drug substances, lipids, lipid formulations, and lipid production methods. An effective partner must also possess the necessary unique analytical capabilities for LNP characterization and the ability to support clients from concept to commercialization.

In this article, explore the following topics:

  • The Importance of LNPs for mRNA Therapies
  • Pathway to Approval
  • Conventional Liposomes vs. Nucleic Acid LNPs
  • Bringing a Breadth of Lipid Nanoparticle Knowledge and Capabilities to the Table
  • Future Opportunities for Lipid Delivery
  • Supporting the Entire Value Chain

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online